Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Vasospasm, Intracranial

ClinicalTrials.gov lists 81 trials for Vasospasm, Intracranial or a narrower condition beneath it. Idorsia Pharmaceuticals Ltd. has the most among industry and government lead sponsors, with 3.

MeSH D020301 Nervous System Diseases C10 C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 4 Phase 1/2 Phase 1/2 4 Phase 2 Phase 2 11 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 4 Phase 4 Phase 4 4 Not applicable Not applicable 29 Observational Observational 23 Phase 1 Phase 1 4 Phase 1/2 Phase 1/2 4 Phase 2 Phase 2 11 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 4 Phase 4 Phase 4 4 Not applicable Not applicable 29 Observational Observational 23

Trials per phase

81 of the 81 trials are tagged with Vasospasm, Intracranial itself; the rest are tagged with a narrower condition beneath it.

Get the Vasospasm, Intracranial report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Vasospasm, Intracranial trials start? (23)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 8

2004: 1 trials (Phase 4 1) 2005: 1 trials (Phase 2 1) 2006: 2 trials (Observational 1, Not applicable 1) 2007: 6 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2/3 1) 2008: 3 trials (Observational 2, Phase 2 1) 2009: 5 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 1/2 1) 2010: 5 trials (Observational 1, Phase 2 2, Phase 1 2) 2011: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 2012: 2 trials (Observational 1, Phase 2 1) 2013: 1 trials (Phase 2 1) 2014: 7 trials (Not applicable 5, Phase 2 1, Phase 1 1) 2015: 4 trials (Observational 1, Not applicable 1, Phase 1/2 2) 2016: 8 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 2 3, Phase 1 1) 2017: 2 trials (Not applicable 2) 2018: 3 trials (Not applicable 2, Phase 1/2 1) 2019: 3 trials (Phase 4 2, Phase 2 1) 2020: 5 trials (Observational 3, Not applicable 2) 2021: 4 trials (Observational 2, Not applicable 2) 2022: 3 trials (Observational 1, Not applicable 1, Phase 2/3 1) 2023: 2 trials (Not applicable 2) 2024: 5 trials (Observational 2, Not applicable 3) 2025: 1 trials (Observational 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 3
2025 1
2024 5
2023 2
2022 3
2021 4
2020 5
2019 3
2018 3
2017 2

No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 29 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 43 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Vasospasm, Intracranial trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 4
Phase 1/2 4
Phase 2 11
Phase 2/3 2
Phase 3 4
Phase 4 4
Not applicable 29
Observational 23

How many Vasospasm, Intracranial trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 3
Recruiting 6
Enrolling by invitation 1
Active, not recruiting 3
Completed 28

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Vasospasm, Intracranial trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Idorsia Pharmaceuticals Ltd. 3
HeadSense Medical 2
Vesalio 2
General Committee of Teaching Hospitals and Institutes, Egypt 1

Which drugs are being tested for Vasospasm, Intracranial? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Nimodipine 2
NICARDIPINE 2

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Stellate Ganglion Block 4
Clazosentan 15 mg/h 2
Sildenafil Citrate 50 mg, 3 times a day 1
Sildenafil Citrate, 25 mg, 3 times a day. 1
Nicardipine + Verapamil + Nitroglycerin 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Vasospasm, Intracranial trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Symptomatic Cerebral Vasospasm 9 1
Cerebral infarct secondary to vasospasm 4 1
Pulmonary edema 4 1
Anemia 3 1
Death 3 1

Which publications cover Vasospasm, Intracranial? (263)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages